How to Find the Right Vaccine CDMO

There is no single type of vaccine manufacturing facility.

A protein-based vaccine, viral vector vaccine, mRNA vaccine, and other vaccine platforms can require very different manufacturing processes.

That makes the term vaccine CDMO broad.

It is useful for discovery, but the sponsor should quickly move to a more specific question:

Which manufacturer supports the platform and manufacturing workflow our vaccine actually requires?

That is where meaningful CDMO comparison begins.

A vaccine CDMO provides development and manufacturing services for vaccine programs.

Depending on the technology and provider, services may include:

• process development
• antigen manufacturing
• vector manufacturing
• mRNA production
• formulation
• adjuvant handling
• analytical development
• GMP manufacturing
• fill finish
• packaging
• stability testing
• clinical supply
• commercial manufacturing

Not every vaccine CDMO supports every vaccine platform.

Depending on the program, the vaccine may involve:

• recombinant protein
• viral vector
• nucleic acid
• other biological or specialized manufacturing platforms

Each can create different requirements for:

• facility
• equipment
• raw materials
• process development
• analytics
• formulation
• scale

A manufacturer's general vaccine experience is less useful than its experience with the relevant platform.

A sponsor may need:

• antigen or drug substance manufacturing
• formulation
• adjuvant handling
• sterile fill finish
• packaging
• an integrated end-to-end solution

Those are different sourcing scopes.

Before comparing CDMOs, define where the sponsor's process begins and where the CDMO's responsibility is expected to end.

Early vaccine programs may require meaningful process-development work before GMP manufacturing.

That may involve:

• upstream optimization
• purification
• formulation development
• analytical methods
• scale-up
• technology transfer

If the manufacturing process is still evolving, development support can be as important as production infrastructure.

A facility that can manufacture the product is not automatically equipped to help develop it.

The final vaccine may require more than a manufactured antigen.

Sponsors may need to consider:

• formulation
• excipients
• adjuvants
• stability
• concentration
• presentation

A CDMO's formulation capabilities should therefore be evaluated alongside manufacturing capabilities where relevant.

Some vaccines use adjuvants as part of the final formulation.

If an adjuvant is required, the sponsor should understand:

• whether the CDMO has experience with it
• how it is sourced
• how it is incorporated into the process
• whether special equipment or handling is required

The exact requirements are product-specific.

This should be addressed during technical evaluation rather than assumed from a general vaccine capability statement.

Vaccine programs can require extensive analytical testing.

Depending on the platform, sponsors may need methods related to:

• identity
• purity
• potency
• concentration
• product-specific attributes
• impurities
• stability
• sterility

Analytical methods may still be under development in an early program.

A sponsor should understand how much analytical support the CDMO can provide.

For many vaccine programs, sterile filling is an important part of the manufacturing plan.

Sponsors should consider:

• container format
• batch size
• filling equipment
• lyophilization if required
• inspection
• packaging
• scheduling

Fill finish may occur at the same CDMO or at a separate facility.

That decision can affect transfer risk and project timing.

Clinical vaccine manufacturing and large-scale supply can require very different infrastructure.

An early-stage program may benefit from:

• smaller batches
• flexibility
• development support

A later-stage program may need:

• larger production scale
• validated processes
• greater capacity
• long-term supply planning

The manufacturing strategy should reflect what the program needs now and what it may need later.

A vaccine CDMO may operate several sites with different capabilities.

Sponsors should understand which facility would actually support the project.

That site may differ from the parent company's broader marketing in terms of:

• platform
• equipment
• scale
• analytical capability
• fill finish
• regulatory history

The facility should become the focus of detailed diligence.

Facility-level regulatory information can provide useful context during preliminary diligence.

Sponsors may review available FDA Form 483 history where relevant.

The existence of a historical observation should not be interpreted as an automatic pass or fail.

Formal quality and regulatory qualification remains with the sponsor.

Vaccine manufacturing schedules can depend on:

• raw materials
• process-development work
• production campaigns
• analytical testing
• formulation
• fill finish

Sponsors should ask for the complete project timeline rather than only the final manufacturing date.

Availability can change, so current capacity should be confirmed directly with the CDMO.

Pharma Connect Navigator helps sponsors identify potential manufacturing partners based on the requirements of their program.

Sponsors can define modality, development stage, required manufacturing capabilities, scale, regulatory expectations, timing, geography, budget, and support needs.

PCN helps identify potentially relevant CDMO companies and facilities and gives teams a structured way to compare project fit.

Sponsors can investigate available facility information, manufacturing capabilities, equipment, and regulatory context before deciding which vaccine CDMOs appear worth advancing.

Once a manufacturer appears relevant, the sponsor can request a structured introduction.

PCN supports early sourcing and preliminary diligence. Formal technical and quality qualification remains the sponsor's responsibility.